Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00167934
Status:
COMPLETED
Last Update Posted:
2020-02-10
First Post:
2005-09-09
Brief Title:
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Metabolic Effects of Valproate and Antipsychotic Therapy
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the metabolic processes responsible for high levels of blood glucose metabolism disorders and weight gain in people with schizophrenia who have been treated with antipsychotic medications in combination with valproate
Detailed Description:
This project aims to study the whole-body metabolic processes responsible for hyperglycemia dyslipidemia and increased adiposity in schizophrenia patients treated with antipsychotic medications in combination with valproate The project hypothesizes that combined treatment with valproate and antipsychotic medications will decrease insulin sensitivity at the level of skeletal muscle liver and adipose tissue in comparison to antipsychotic monotherapy The decrease in insulin sensitivity is hypothesized to be associated with defects in glucose and lipid metabolism and increased adiposity
Treatment effects of antipsychoticvalproate combination therapy on different components of insulin secretion and action and treatment effects on abdominal versus peripheral adiposity are unknown despite the availability of gold-standard methods and the prognostic significance of these issues Relevant data are needed to target basic research to identify the potential for acute and long-term complications and to plan therapeutic interventions The following specific aims will be addressed in non-diabetic schizophrenia patients treated with atypical antipsychotics who will be randomized to open label treatment with either valproate or no adjuvant Evaluations are performed at baseline and 3 months of treatment
Treatment effects of antipsychoticvalproate combination therapy on different components of insulin secretion and action and treatment effects on abdominal versus peripheral adiposity are unknown despite the availability of gold-standard methods and the prognostic significance of these issues Relevant data are needed to target basic research to identify the potential for acute and long-term complications and to plan therapeutic interventions The following specific aims will be addressed in non-diabetic schizophrenia patients treated with atypical antipsychotics who will be randomized to open label treatment with either valproate or no adjuvant Evaluations are performed at baseline and 3 months of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DAHBR AK-TNET1 | US NIH GrantContract | None | httpsreporternihgovquickSearchK23MH067795 |
| K23MH067795 | NIH | None | None |